Market News

Johnston Asset Management Decreased By $8.13 Million Its Facebook (FB) Holding; Omeros (OMER) Shorts Raised By 6.95%

Omeros Corporation (NASDAQ:OMER) Logo

Johnston Asset Management Corp decreased Facebook Inc (FB) stake by 45.88% reported in 2018Q1 SEC filing. Johnston Asset Management Corp sold 51,120 shares as Facebook Inc (FB)’s stock declined 0.01%. The Johnston Asset Management Corp holds 60,290 shares with $9.63M value, down from 111,410 last quarter. Facebook Inc now has $580.32B valuation. The stock decreased 0.51% or $1.02 during the last trading session, reaching $200.48. About 3.23M shares traded. Facebook, Inc. (NASDAQ:FB) has risen 21.69% since June 22, 2017 and is uptrending. It has outperformed by 9.12% the S&P500. Some Historical FB News: 25/03/2018 – Facebook has been scraping years worth of Android call and text data, according to a report; 20/03/2018 – GBH’s Ives Says Facebook’s Data Leak Is a ‘Major Black Eye’ (Video); 26/03/2018 – FTC opens probe into Facebook privacy practices; 17/04/2018 – MEDIA-Tech firms to pledge not to assist governments in cyberattacks – NYT; 22/03/2018 – Facebook is vulnerable to a user revolt and a government crackdown, says Niall Ferguson; 11/04/2018 – Star Tribune: Breaking (@AP): Facebook CEO acknowledges his own personal data was sold to third parties in congressional; 22/05/2018 – EUROPEAN FIRMS SAY HAVE HIRED MORE PEOPLE BY USING FACEBOOK TOOLS-ZUCKERBERG; 22/03/2018 – U.S. Senate subcommittee seeks information on Facebook data; 30/04/2018 – MFS Growth Fund Adds Dropbox, Cuts Facebook; 10/04/2018 – FOX 5 Atlanta: #BREAKING: WASHINGTON (AP) — Facebook CEO Mark Zuckerberg says company is working with special counsel Robert

Omeros Corporation (NASDAQ:OMER) had an increase of 6.95% in short interest. OMER’s SI was 9.81 million shares in June as released by FINRA. Its up 6.95% from 9.17M shares previously. With 2.83 million avg volume, 4 days are for Omeros Corporation (NASDAQ:OMER)’s short sellers to cover OMER’s short positions. The stock decreased 0.38% or $0.07 during the last trading session, reaching $18.38. About 43,417 shares traded. Omeros Corporation (NASDAQ:OMER) has risen 24.49% since June 22, 2017 and is uptrending. It has outperformed by 11.92% the S&P500. Some Historical OMER News: 24/05/2018 – Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin; 11/04/2018 – OMEROS MAY BORROW UP TO AN ADDED $45M ON OR BEFORE MAY 20; 22/04/2018 – DJ Omeros Corporation, Inst Holders, 1Q 2018 (OMER); 24/05/2018 – OMEROS IN SETTLEMENT PACT WITH LUPIN RESOLVING PATENT SUIT; 12/04/2018 – OMIDRIA® Added to Veterans Health Administration National Formulary; 26/04/2018 – FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy; 26/04/2018 – OMEROS CORP OMER.O – DISCUSSIONS ONGOING WITH FDA AND EUROPEAN REGULATORS FOR EXPEDITED APPROVAL OF OMS721; 24/05/2018 – OMEROS – LUPIN GRANTED LICENSE TO MAKE, SELL GENERIC VERSION OF OMIDRIA BETWEEN PERMITTED LAUNCH DATE & LATEST EXPIRATION OF CO’S U.S. PATENTS; 11/04/2018 – OMEROS CORP – AMENDED ITS EXISTING CREDIT FACILITY WITH CERTAIN AFFILIATES OF CRG LP; 10/05/2018 – Omeros 1Q Loss $30.1M

Among 55 analysts covering Facebook (NASDAQ:FB), 51 have Buy rating, 2 Sell and 2 Hold. Therefore 93% are positive. Facebook had 274 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Focus List” rating by Bank of America on Tuesday, July 21. Mizuho maintained the stock with “Buy” rating in Tuesday, September 19 report. The stock of Facebook, Inc. (NASDAQ:FB) has “Buy” rating given on Thursday, April 28 by Suntrust Robinson. The rating was maintained by Deutsche Bank with “Buy” on Thursday, April 28. The firm has “Buy” rating by Jefferies given on Thursday, January 28. The stock of Facebook, Inc. (NASDAQ:FB) earned “Outperform” rating by Credit Suisse on Monday, April 18. On Thursday, February 1 the stock rating was maintained by Credit Suisse with “Buy”. Deutsche Bank maintained the stock with “Buy” rating in Thursday, November 5 report. Evercore maintained the stock with “Buy” rating in Thursday, April 28 report. The rating was maintained by Nomura with “Buy” on Thursday, April 28.

Since January 9, 2018, it had 0 buys, and 70 selling transactions for $3.22 billion activity. $44.53 million worth of stock was sold by Zuckerberg Mark on Wednesday, February 28. On Monday, April 2 the insider Sandberg Sheryl sold $8.57 million. 1.26 million Facebook, Inc. (NASDAQ:FB) shares with value of $231.84 million were sold by Koum Jan. $3.36M worth of Facebook, Inc. (NASDAQ:FB) shares were sold by FISCHER DAVID B.. On Wednesday, June 13 the insider Stretch Colin sold $144,413. On Tuesday, June 12 the insider Schroepfer Michael Todd sold $7.31 million. 10,600 shares valued at $2.03 million were sold by Cox Christopher K on Monday, June 11.

More notable recent Facebook, Inc. (NASDAQ:FB) news were published by: Nasdaq.com which released: “Time to Face Facts and Short Facebook Above $200” on June 21, 2018, also Nasdaq.com with their article: “Trade of the Day: Facebook, Inc. (FB)” published on June 19, 2018, Thestreet.com published: “Facebook Messenger Could Bring in Billions of Dollars — Here’s How” on June 20, 2018. More interesting news about Facebook, Inc. (NASDAQ:FB) were released by: Nasdaq.com and their article: “Subscription Groups Is Yet Another Billion-Dollar Opportunity for Facebook Stock” published on June 21, 2018 as well as Bizjournals.com‘s news article titled: “Facebook hires company to explore $2.4 billion Dumbarton project that would help connect its Fremont and Menlo Park …” with publication date: June 21, 2018.

Analysts await Facebook, Inc. (NASDAQ:FB) to report earnings on July, 25. They expect $1.72 EPS, up 30.30% or $0.40 from last year’s $1.32 per share. FB’s profit will be $4.98 billion for 29.14 P/E if the $1.72 EPS becomes a reality. After $1.69 actual EPS reported by Facebook, Inc. for the previous quarter, Wall Street now forecasts 1.78% EPS growth.

Investors sentiment decreased to 0.87 in 2018 Q1. Its down 0.34, from 1.21 in 2017Q4. It is negative, as 145 investors sold FB shares while 712 reduced holdings. 173 funds opened positions while 573 raised stakes. 1.65 billion shares or 2.41% more from 1.61 billion shares in 2017Q4 were reported. Old Mutual Glob Invsts (Uk) Limited reported 2.12 million shares stake. Whittier Tru Communications owns 116,679 shares. Gm Advisory holds 0.88% of its portfolio in Facebook, Inc. (NASDAQ:FB) for 18,295 shares. Hbk Invs LP reported 131,492 shares. Moreover, Middleton & Ma has 2.24% invested in Facebook, Inc. (NASDAQ:FB) for 78,458 shares. Philadelphia Tru Com has 191,307 shares. Thompson Davis & Inc owns 1,500 shares for 0.63% of their portfolio. Sterling Capital Mngmt Limited Liability Corporation owns 0.06% invested in Facebook, Inc. (NASDAQ:FB) for 40,215 shares. Plancorp Limited Liability Company has invested 0.1% in Facebook, Inc. (NASDAQ:FB). Price Michael F reported 0.13% of its portfolio in Facebook, Inc. (NASDAQ:FB). First Hawaiian Bank & Trust accumulated 2,068 shares. Jpmorgan Chase & Communications owns 0.64% invested in Facebook, Inc. (NASDAQ:FB) for 18.83M shares. Apg Asset Mngmt Nv owns 0.95% invested in Facebook, Inc. (NASDAQ:FB) for 3.80 million shares. Hall Kathryn A holds 191,098 shares or 19.42% of its portfolio. Fmr Ltd owns 2.27% invested in Facebook, Inc. (NASDAQ:FB) for 119.63 million shares.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $887.62 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

Among 9 analysts covering Omeros (NASDAQ:OMER), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Omeros had 38 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Omeros Corporation (NASDAQ:OMER) has “Buy” rating given on Thursday, January 4 by H.C. Wainwright. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, January 23 report. The stock of Omeros Corporation (NASDAQ:OMER) has “Hold” rating given on Friday, March 2 by Needham. Cantor Fitzgerald initiated the shares of OMER in report on Friday, June 3 with “Buy” rating. The firm earned “Buy” rating on Thursday, April 19 by H.C. Wainwright. The firm earned “Buy” rating on Wednesday, August 2 by Maxim Group. H.C. Wainwright maintained it with “Buy” rating and $30.0 target in Monday, March 5 report. As per Wednesday, May 16, the company rating was maintained by Wedbush. Maxim Group maintained it with “Buy” rating and $2300 target in Tuesday, June 13 report. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, May 3 report.

More news for Omeros Corporation (NASDAQ:OMER) were recently published by: Seekingalpha.com, which released: “Is It Time To Close Out The Omeros Corporation Trade?” on June 13, 2018. Seekingalpha.com‘s article titled: “Omeros Corporation: OMS721 In HSCT-TMA And IgAN Plus Omidria Worth $2.5 Billion” and published on June 05, 2018 is yet another important article.

Since January 3, 2018, it had 0 buys, and 3 selling transactions for $1.93 million activity. The insider Kelbon Marcia S. sold $1.34M. On Monday, May 14 the insider JACOBSEN MICHAEL A sold $566,160.

Facebook, Inc. (NASDAQ:FB) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *